Cargando…

'Tumour volume' as a predictor of survival after resection of non-small-cell lung cancer (NSCLC)

Many factors have been individually related to outcome in populations of non-small-cell lung cancer (NSCLC) patients. Factors responsible for the outcome of an individual after surgical resection are poorly understood. We have examined the importance of 'tumour volume' in determining progn...

Descripción completa

Detalles Bibliográficos
Autores principales:	Jefferson, M. F., Pendleton, N., Faragher, E. B., Dixon, G. R., Myskow, M. W., Horan, M. A.
Formato:	Texto
Lenguaje:	English
Publicado:	Nature Publishing Group 1996
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2074647/ https://www.ncbi.nlm.nih.gov/pubmed/8695364

Ejemplares similares

Relationship between vascularity, age and survival in non-small-cell lung cancer.
por: Chandrachud, L. M., et al.
Publicado: (1997)

p53 expression in normal and dysplastic bronchial epithelium and in lung carcinomas.
por: Walker, C., et al.
Publicado: (1994)

Immunotherapy and Vaccination in Surgically Resectable Non-Small Cell Lung Cancer (NSCLC)
por: Chiu, Li-Chung, et al.
Publicado: (2021)

Mitochondrial Variations in Non-Small Cell Lung Cancer (NSCLC) Survival
por: Wang, Zhaoxi, et al.
Publicado: (2015)

Modified Glasgow Prognostic Score at Recurrence Predicts Poor Survival in Resected Non-Small Cell Lung Cancer (NSCLC) Patients
por: Lv, Yongbin, et al.
Publicado: (2017)

Survival in Patients with Neuroendocrine Tumours of the Small Intestine: Nomogram Validation and Predictors of Survival
por: Levy, Sonja, et al.
Publicado: (2020)

Genetic variation in the eicosanoid pathway is associated with non-small-cell lung cancer (NSCLC) survival
por: Sausville, Lindsay N., et al.
Publicado: (2017)

Expression of the BCL-2 protein in normal and dysplastic bronchial epithelium and in lung carcinomas.
por: Walker, C., et al.
Publicado: (1995)

Multidisciplinary collaborative gross tumour volume definition for lung cancer radiotherapy: a prospective study
por: Hollingdale, Abigail E., et al.
Publicado: (2011)

Resectable IIIA-N2 Non-Small-Cell Lung Cancer (NSCLC): In Search for the Proper Treatment
por: Brascia, Debora, et al.
Publicado: (2020)

Association between the Preoperative Standard Uptake Value (SUV) and Survival Outcomes after Robotic-Assisted Segmentectomy for Resectable Non-Small Cell Lung Cancer (NSCLC)
por: Aboukheir Aboukheir, Aihab, et al.
Publicado: (2023)

Clinicopathological predictors of survival in resected primary lung adenocarcinoma
por: Jhala, Hiral, et al.
Publicado: (2022)

Management of Resectable Stage III-N2 Non-Small-Cell Lung Cancer (NSCLC) in the Age of Immunotherapy
por: Mielgo-Rubio, Xabier, et al.
Publicado: (2021)

Tumour volume is a predictor of lymphovascular invasion in differentiated small thyroid cancer
por: Vikneson, Krishna, et al.
Publicado: (2022)

Staging of non-small cell lung cancer (NSCLC)
por: Rankin, S C
Publicado: (2006)

Metabolic Tumour Volume as a Predictor of Survival for Sinonasal Tract Squamous Cell Carcinoma
por: Suzuki, Hidenori, et al.
Publicado: (2022)

The value of cell-free circulating tumour DNA profiling in advanced non-small cell lung cancer (NSCLC) management
por: Fernandes, Maria Gabriela O., et al.
Publicado: (2021)

Loss of tumour-specific ATM protein expression is an independent prognostic factor in early resected NSCLC
por: Petersen, Lars F., et al.
Publicado: (2017)

Second-line therapy improves overall survival in primary refractory non-small cell lung cancer (NSCLC) patients
por: Rothschild, S.I., et al.
Publicado: (2021)

The presence of intraepithelial CD45RO+ cells in resected lymph nodes with metastases from NSCLC patients is an independent predictor of disease-specific survival
por: Kilvaer, Thomas K, et al.
Publicado: (2016)

Gross tumour volume radiomics for prognostication of recurrence & death following radical radiotherapy for NSCLC
por: Hindocha, Sumeet, et al.
Publicado: (2022)

Repeatability of [(18)F]FDG PET/CT total metabolic active tumour volume and total tumour burden in NSCLC patients
por: Kolinger, Guilherme D., et al.
Publicado: (2019)

Emerging role of gefitinib in the treatment of non-small-cell lung cancer (NSCLC)
por: Tiseo, M, et al.
Publicado: (2010)

Predictive factors associated with prolonged survival in patients with advanced non-small-cell lung cancer (NSCLC) treated with gefitinib
por: Satouchi, M, et al.
Publicado: (2007)

Surgical resection and survival of patients with unsuspected single node positive lung cancer (NSCLC) invading the descending aorta
por: Wex, Peter, et al.
Publicado: (2009)

The Interplay between MicroRNAs and Cellular Components of Tumour Microenvironment (TME) on Non-Small-Cell Lung Cancer (NSCLC) Progression
por: Lee, Sook Shien, et al.
Publicado: (2019)

ALK‐rearrangement in non‐small‐cell lung cancer (NSCLC)
por: Du, Xue, et al.
Publicado: (2018)

p53 and VEGF expression are independent predictors of tumour recurrence and survival following curative resection of gastric cancer
por: Fondevila, C, et al.
Publicado: (2004)

The value of disease-free survival (DFS) and osimertinib in adjuvant non-small-cell lung cancer (NSCLC): an international Delphi consensus report
por: Hardenberg, M.C., et al.
Publicado: (2022)

Survival predictors after resection of lung metastases of head or neck cancers
por: Yotsukura, Masaya, et al.
Publicado: (2015)

Tumour markers for prediction of survival and monitoring of remission in small cell lung cancer.
por: Johnson, P. W., et al.
Publicado: (1993)

A retrospective study evaluating the pretreatment tumor volume (PTV) in non-small cell lung cancer (NSCLC) as a predictor of response to program death-1 (PD-1) inhibitors
por: Nagasaka, Misako, et al.
Publicado: (2019)

The Effect of Lung Resection for NSCLC on Circulating Immune Cells: A Pilot Study
por: Phillips, Joseph D., et al.
Publicado: (2023)

Tumour necrosis factor-alpha expression in tumour islets confers a survival advantage in non-small cell lung cancer
por: Ohri, Chandra M, et al.
Publicado: (2010)

Artificial intelligence quantified tumour-stroma ratio is an independent predictor for overall survival in resectable colorectal cancer
por: Zhao, Ke, et al.
Publicado: (2020)

Neoadjuvant durvalumab for resectable non-small-cell lung cancer (NSCLC): results from a multicenter study (IFCT-1601 IONESCO)
por: Wislez, Marie, et al.
Publicado: (2022)

Mitochondrial markers predict survival and progression in non-small cell lung cancer (NSCLC) patients: Use as companion diagnostics
por: Sotgia, Federica, et al.
Publicado: (2017)

SEOM clinical guidelines for the treatment of non-small cell lung cancer (NSCLC) 2015
por: García-Campelo, R., et al.
Publicado: (2015)

Advances in radiological staging of non-small cell lung cancer (NSCLC)
por: Rankin, S C
Publicado: (2004)

ASCO 2020 non-small lung cancer (NSCLC) personal highlights
por: Horvath, Lena, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_54v5fqf47gok9ugh965gp0rfav